This program’s overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. Topics discussed will include choosing the right type of factor assays for monitoring newer factor and non-factor products for hemophilia management, optimal role of newer technologies like next generation sequencing for diagnosis of coagulation disorders, optimal laboratory evaluation of inherited platelet disorders, update on recent advances in the diagnosis of heparin induced thrombocytopenia and role of measuring direct acting oral anticoagulants.

Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.